JNJ 26489112

Drug Profile

JNJ 26489112

Alternative Names: 14C-JNJ-26489112; 26489112; JNJ-26489112

Latest Information Update: 18 Oct 2013

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antidepressants; Antiepileptic drugs
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Epilepsy; Major depressive disorder

Most Recent Events

  • 01 Oct 2013 Discontinued - Phase-I for Epilepsy (in volunteers) in Belgium (PO)
  • 01 Oct 2013 Discontinued - Phase-II for Epilepsy in USA (PO)
  • 12 Mar 2012 Discontinued - Phase-II for Depressive disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top